BCL11A and Schnyder corneal dystrophy: Two phase 1/2 clinical trials based on CRISPR/Cas9-mediated BCL11A enhancer editing are currently ongoing (NCT03655678 and NCT03745287 for transfusion dependent β-thalassemia and SCD, respectively).